Diagnosis, prevention and treatment of chronic heart failure: what the therapist of the outpatient health care unit should know (according to the recommendations of the European Society of Cardiology for the diagnosis and treatment of acute and chronic heart failure in 2016)


Cite item

Full Text

Abstract

In the article, the main provisions of the recommendations of the European Society of Cardiology and the Association for Heart Failure 2016 are presented in the abstract. The new classification is presented, the approaches to diagnostics and pharmacological treatment of chronic heart failure are highlighted, attention is paid to the prevention of development of clinically significant heart failure and multidisciplinary approach in managing patients with this pathology.

About the authors

V. N Larina

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Email: larinav@mail.ru
д-р мед. наук, проф. каф. поликлинической терапии лечебного фак-та 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

I. I Chukaeva

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., зав. каф. поликлинической терапии лечебного фак-та 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

M. G Bubnova

National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation

Email: mbubnova@gnicpm.ru
д-р мед. наук, проф., рук. отд. реабилитации и вторичной профилактики сочетанной патологии с лаб. профилактики атеросклероза и тромбоза 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3

References

  1. Ponikowski P, Voors A, Anker S. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016. doi: 10.1093/eurheartj/ehw128
  2. Lam C, Solomon S. The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). Eur J Heart Fail 2014; 16: 1049-55.
  3. Thibodeau J, Turer A, Gualano S. et al. Characterization of a novel symptom of advanced heart failure: bendopnea. JACC Heart Fail 2014; 2: 24-31.
  4. Wright J, Williamson J, Whelton P. et al. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103-16.
  5. McMurray J, Packer M, Desai A. and PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
  6. Nieuwlaat R, Eurling L.W, Cleland J.G. et al. Atrial fibrillation and heart failure in cardiology practice. Results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol 2009; 53: 1690.
  7. Connolly S, Ezekowitz M, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 17; 361 (12): 1139-51.
  8. Patel M, Mahaffey K, Garg J. et al, and the ROCKET AF Steering Committee, for the ROCKET AF Investigator. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365: 883-91.
  9. Granger C.B, Alexander J.H, McMurray J.J. et al. Apixaban versus warfarin in patients with atrial fib- rillation. N Engl J Med 2011; 365 (11): 981-92.
  10. McMurray J.J.V, Ezekowitz J.A, Lewis B.S. et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation insights from the ARISTOTLE trial. Circ Heart Fail 2013; 6 (3): 451-60.
  11. Connolly S, Eikelboom J, Joyner C. et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 3 (364, 9): 806-17.
  12. Heidbuchel H, Verhamme P, Alings M. et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17 (10): 1467-507.
  13. Frost C, Nepal S, Wang J. et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013; 76 (5): 776-86.

Copyright (c) 2017 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies